Welcome by Chairs

Solange Peters & Alfredo Addeo

Advancements in Lung Cancer Diagnostics: Current Guidelines and Emerging Tests

Anne Schultheis (Germany)

Novel Therapeutic Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

Anne-Marie Dingemans (Netherlands)

Rare But Actionable: How To Target for RET, METex14 and NTRK

Roberto Ferrara (Italy)

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

Biagio Ricciuti (USA)

The Emerging Role of ADCs in Lung Cancer: Navigating Timing and Applications for Optimal Use

Jarushka Naidoo (Ireland)

Surgical Dilemmas in NSCLC: Defining Resectability for Optimal Patient Outcomes in the IO Era

Nuria maria novoa (spain)

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

Jordi Remon (France)

DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC

• We Must Seize Every Opportunity To Cease IO

  Giannis Mountzios (Greece)

• We Must Maximize IO Benefits Through Prolonged Therapy

  Sandip Patel (USA)

Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies

Stephen Liu (USA)

Open Questions, Patient Cases & Guidelines

Panel Discussion With All